Trial · NCT00632749
Participant flow70
How many started, completed or left each group, period by period.
1 to 20 of 70
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 4 | |
| Overall Study | STARTED | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 5 | |
| Overall Study | STARTED | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 3 | |
| Overall Study | STARTED | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 4 | |
| Overall Study | STARTED | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 7 | |
| Overall Study | STARTED | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 8 | |
| Overall Study | STARTED | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 5 | |
| Overall Study | STARTED | 40 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 4 | |
| Overall Study | STARTED | 80 mg BI 811283+ 20 mg Cytarabine - Treatment Schedule B | 5 | |
| Overall Study | STARTED | 160 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 3 | |
| Overall Study | STARTED | 240 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 7 | |
| Overall Study | STARTED | 300 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 4 | |
| Overall Study | STARTED | 360 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 3 | |
| Overall Study | STARTED | 420 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule B | 6 | |
| Overall Study | Treated | 5 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 4 | |
| Overall Study | Treated | 15 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 3 | |
| Overall Study | Treated | 30 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 3 | |
| Overall Study | Treated | 60 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 4 | |
| Overall Study | Treated | 100 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 7 | |
| Overall Study | Treated | 120 mg BI 811283 + 20 mg Cytarabine - Treatment Schedule A | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00632749/flow